Patents by Inventor Julie Hixon

Julie Hixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide hydrogels and use thereof
    Patent number: 11661439
    Abstract: This disclosure provides novel anionic amphiphilic ?-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.
    Type: Grant
    Filed: December 17, 2017
    Date of Patent: May 30, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Schneider, Scott Walsh, Stephen Miller, Yuji Yamada, Scott Durum, Caroline Andrews, Wenqing Li, Julie Hixon, Steven Tau
  • IL-7R-alpha SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20220064309
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Application
    Filed: August 2, 2021
    Publication date: March 3, 2022
    Applicants: University of Maryland, College Park, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
    Patent number: 11111306
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 7, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • PEPTIDE HYDROGELS AND USE THEREOF
    Publication number: 20210079042
    Abstract: This disclosure provides novel anionic amphiphilic ?-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.
    Type: Application
    Filed: December 17, 2017
    Publication date: March 18, 2021
    Applicants: Health and Human Services
    Inventors: Joel Schneider, Scott Walsh, Stephen Miller, Yuji Yamada, Scott Durum, Caroline Andrews, Wenqing Li, Julie Hixon, Steven Tau
  • IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20190315875
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 17, 2019
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
    Patent number: 10392441
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: August 27, 2019
    Assignees: United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
  • IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20180251561
    Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.
    Type: Application
    Filed: October 7, 2016
    Publication date: September 6, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, University of Maryland, College Park
    Inventors: Scott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi